Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of 4-AcO-DMT can be broken down into two components all of which progressively intensify proportional to dosage.
The head space of 4-AcO-DMT is described by many as extremely relaxing, profound and stoning in its style when compared to other commonly used psychedelics such as LSD or 2C-B which tend to be energetic and stimulating. It contains a large number of psychedelic typical and unique cognitive effects.
4-AcO-DMT presents a full and complete array of possible visual enhancements.
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of ayahuasca and 2C-E than LSD. It can be comprehensively described as structured in its organization, organic in geometric style, intricate in complexity, large in size, fast and smooth in motion, colourful in scheme, glossy in colour, blurred in its edges and rounded in its corners. They have a very 'natural' feel to them and at higher dosages are significantly more likely to result in states of Level 7B visual geometry over Level 7A.
4-AcO-DMT and its various other forms produce a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics.
The auditory effects of 4-AcO-DMT are common in their occurrence and exhibit a full range of effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
4-AcO-DMT is considered non-addictive with low potential for abuse. It is not associated with compulsive use, and users commonly report a self-regulating quality where the desire for subsequent use is naturally limited.
Physical dependence is extremely unlikely due to its pharmacological similarity to psilocybin.
The exact toxic dose is unknown as 4-AcO-DMT has not undergone formal toxicological studies. It is assumed to have a similar safety profile to psilocybin mushrooms, which are known to be physiologically non-toxic, although there is no hard data to support this claim. One experience report describes significant cardiovascular distress at 150mg, though the compound's possible harms remain formally unstudied.
Psychedelics including 4-AcO-DMT have been known to trigger latent psychological and mental problems in individuals with a family history of schizophrenia or early onset mental illness. Risk is primarily associated with predisposed individuals rather than the general population of users.
Seizures are rarely observed and are thought to primarily affect those already predisposed to them, particularly in physically taxing conditions such as being overheated, dehydrated, undernourished, or fatigued.
4-AcO-DMT was first synthesized in 1963 by the Swiss chemists Albert Hofmann and Franz Troxler during systematic investigations into psilocin analogs conducted at Sandoz Laboratories. The compound, along with several other psilocin esters, was patented by Sandoz Ltd on January 16, 1963. Notably,…
Classified as a Schedule 9 prohibited substance under the Poisons Standard (October 2015) as an analog of psilocin. This classification restricts manufacture, possession, sale, or use except for approved medical or scientific research purposes.
Listed as a controlled substance under Portaria SVS/MS nº 344. Possession, production, and sale are prohibited.
Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since January 24, 1974, as it is classified as an ester of DMT. Manufacturing, possession, importation, exportation, purchase, sale, procurement, and dispensing without a license are illegal.
Prohibited under Italian drug law as an ester of a controlled substance (psilocin). Possession, production, and distribution are criminal offenses.
Added to the Narcotic Drugs Punishments Act as a Schedule I substance (classified as substances without accepted medical use) on January 25, 2017. Listed as '4-acetoxi-N,N-dimetyltryptamin' in Medical Products Agency regulation HSLF-FS 2017:1.
Classified as a controlled drug. Possession, production, supply, and importation are prohibited under national drug legislation.
Not explicitly scheduled under federal law, but possession or sale for human consumption may be prosecuted under the Federal Analogue Act of 1986, as it is considered an analog of the Schedule I substance psilocin. Can be legally possessed for research purposes when labeled 'not for human consumption.' Additionally, 4-AcO-DMT is listed as a Schedule I controlled substance at the state level in several states, including Alabama (since March 18, 2014).
Importation of 4-AcO-DMT is illegal in Belgium under national drug control legislation.
Banned under national drug legislation except for strictly limited research and therapeutic purposes with appropriate authorization.
Classified as a controlled substance by virtue of being a derivative of DMT under national drug control legislation.
Designated as a controlled substance effective July 29, 2015, under national drug control legislation.
May be considered illegal under Buchstabe B of Swiss narcotics legislation as an ester analog of psilocin. Legal status is interpreted rather than explicitly scheduled.
Controlled as a Class A substance under the Misuse of Drugs Act 1971 because it is an ester of the Class A drug psilocin. Class A offenses carry the most severe penalties in UK drug law.
21 sources cited
